<DOC>
	<DOC>NCT02058537</DOC>
	<brief_summary>The primary goals of this study are to ease the symptoms of patients with Eosinophilic Esophagitis (EoE) and to test the effectiveness of the drug bethanechol in relieving those symptoms.</brief_summary>
	<brief_title>Bethanechol for Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Bethanechol</mesh_term>
	<criteria>Male or Female Age 1875 Symptoms associated with EoE such as dysphagia, heartburn, vomiting, abdominal pain, food impaction Subject has signed informed consent for the administration of bethanechol that informs the patient of potential adverse events Clinically or pathologically proven EoE Known allergy to bethanechol Asthma Pregnant or breastfeeding women Severe neurological problems Severe diabetes Achalasia Known allergy to lidocaine or other local anesthetic Hypothyroidism Peptic ulcer Pronounced bradycardia or hypotension Vasomotor instability Coronary artery disease Epilepsy Parkinsonism Weakened gastrointestinal or bladder wall Mechanical obstruction of the gastrointestinal tract or bladder neck Urinary bladder surgery in the 6 months prior to the study Gastrointestinal resection and anastomosis Spastic gastrointestinal disturbances Acute inflammatory lesions of the gastrointestinal tract Peritonitis Marked vagotonia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>